Are you a journalist?

Get to know ALK

If you have any queries please feel free to contact Media Relations at ALK headquarters or one of our global offices.

The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

News

  • Post date
    08/16/2017
    Six-month interim report (Q2) 2017
  • Post date
    08/08/2017
    Release date of six-month interim report (Q2) 2017 and audio cast
  • Post date
    07/31/2017
    Management change at ALK
  • Post date
    07/07/2017
    Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
  • Post date
    06/20/2017
    ALK symposium reveals early treatment is critical for respiratory allergic disease in children and adolescents
  • Post date
    05/09/2017
    Three-month interim report (Q1) 2017
  • Post date
    05/04/2017
    ALK's HDM SLIT-tablet, ACARIZAX®, approved in Canada
  • Post date
    05/03/2017
    Release date of three-month interim report (Q1) 2017 and audio cast
  • Post date
    04/16/2017
    ACARIZAX® approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis

Media Relations

Per Plotnikof
Vice President,
Corporate Communications,
Investor Relations and Strategic Planning
Phone: +45 22612525
Email: PPIDK@alk.net

Jeppe Ilkjær
Media Relations Manager
Corporate Communications
Phone: +45 30502014
Email: Jeppe.Ilkjaer@alk.net

Journalists are always welcome to contact ALK’s Media Relations team.
Flemming Pedersen, CFO
Helle Skov, EVP Product Supply
Søren Niegel, EVP Commercial Operations
Henrik Jacobi, EVP Research and Development
Production facilities, Hørsholm
Production facilities, Hørsholm
Production facilities, Hørsholm
ALK HQ, Hørsholm
Last updated: 2017.01.11